Epigenetics Market Analysis and Growth Forecast by Regions and Applications to 2025

Posted on 2021-06-23 by researchinsights in Biotech // 0 Comments

San Jose, California , USA, June 23, 2021 — /EPR Network/ —

The global Epigenetics Market is expected to value at USD 22.05 billion in 2025, exhibiting a CAGR of 19.7% during the forecast period of 2018 to 2025. Rapid surge in the product demand is credited to the ever-growing geriatric population and prevalence of chronic diseases. Globally, the epigenetics market is predicted to generate massive revenue over the forecast period, providing numerous opportunities for industry participants to invest in research and development of epigenetics services.

The identification of severity among patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain. High-end demand for latest technologies in healthcare sector and collective research and development (R&D) activities in the area of genetics is anticipated to foster industry growth as well.

Request a Sample Copy of Epigenetics Market Report @ https://www.millioninsights.com/industry-reports/epigenetics-market-size/request-sample

Several diagnostic and testing organization have launched innovative products including antibodies specific for identification of modifications and advanced kits for simple and efficient detection of biomarkers. Furthermore, development of therapeutic drugs by healthcare providers is anticipated to work in favor of the epigenetics market. Introduction of pipeline drugs and rising approval rate from local and international authorities is estimated to augment epigenetics industry growth over the coming years.

Rising approval rate for therapeutic drugs and epigenetics services is the key industry trend over the past few years. For example, Eli Lilly and Co., global pharmaceutical company, has unveiled its product line of advanced therapeutic drugs Ramucirumab (Cyramza), which is recently approved by FDA. Shifting focus towards the epigenetics services by pharmaceutical companies for detecting of methylation markers during cancer treatment is expected to favor epigenetics industry growth. Epigenomics AG has developed Epi proLung BL Reflex Assay that allows simple diagnosis for lung cancer.

The key players are Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc, and Sigma-Aldrich Corp.

Epigenetics Product Outlook (Revenue, USD Million, 2014 – 2025)

Reagents
Kits
ChIP sequencing kit
Whole Genomic Amplification Kit
Bisulfite Conversion kit
RNA sequencing kit
Others
Instruments
Enzymes
Services

Epigenetics Technology Outlook (Revenue, USD Million, 2014 – 2025)

DNA Methylation
Histone Methylation
Histone Acetylation
Large noncoding RNA
MicroRNA Modification
Chromatin structures

Access Epigenetics Market Report with TOC @ https://www.millioninsights.com/industry-reports/epigenetics-market-size

Table of Contents

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Epigenetics Market Variables, Trends & Scope

Chapter 5 Epigenetics Market Product Estimates & Trend Analysis

Chapter 6 Epigenetics Market Technology Estimates & Trend Analysis

Chapter 7 Epigenetics Market Application Estimates & Trend Analysis

Chapter 8 Regional Estimates & Trend Analysis, by Product

Chapter 9 Competitive Landscape

Visit Our Blog: https://marketreportsassistance.wordpress.com

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Matched content

Editor’s pick